The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Open accessAbstract
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and the leading cause of chronic liver disease in the Western world. Twenty per cent of NAFLD individuals develop chronic hepatic inflammation (non-alcoholic steatohepatitis, NASH) associated with cirrhosis, portal hypertension and hepatocellular carcinoma, yet the causes of progression from NAFLD to NASH remain obscure. Here, we show that the NLRP6 and NLRP3 inflammasomes and the effector protein IL-18 negatively regulate NAFLD/NASH progression, as well as multiple aspects of metabolic syndrome via modulation of the gut microbiota. Different mouse models reveal that inflammasome-deficiency-associated changes in the configuration of the gut microbiota are associated with exacerbated hepatic steatosis and inflammation through influx of TLR4 and TLR9 agonists into the portal circulation, leading to enhanced hepatic tumour-necrosis factor (TNF)-α expression that drives NASH progression. Furthermore, co-housing of inflammasome-deficient mice with wild-type mice results in exacerbation of hepatic steatosis and obesity. Thus, altered interactions between the gut microbiota and the host, produced by defective NLRP3 and NLRP6 inflammasome sensing, may govern the rate of progression of multiple metabolic syndrome-associated abnormalities, highlighting the central role of the microbiota in the pathogenesis of heretofore seemingly unrelated systemic auto-inflammatory and metabolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LPS-mediated activation of KCs via TLR4 leading to MyD88-dependent activation of NF-kB, production of proinflammatory cytokines and subsequent liver injury have also been demonstrated for both MASH(214) and ASH(215).”
From The liver as a central "hub" of the immune system: pathophysiological implications (2025) · cites this paper as [214]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Animal studies have demonstrated a direct role of altered intestinal microbiota in steatosis,15 NASH(16), fibrosis17 and liver cancer.18”
From Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling (2023) · cites this paper as [16]
In the citing paper
“In NAFLD models, lack of inflammasomes has been demonstrated to select a pathogenetic microbiota which was associated with a more severe degree of liver injury [226].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [226]
In the citing paper
“Either in patients with NASH or animal models, the expression of inflammasome components was increased, indicating the potential role in the pathogenesis of liver injury [226,227,288,289,290,291].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [226]
In the citing paper
“These results indicate that complex interactions between the diet, the innate immunity, bacteria and intestinal function occurs in the development of NASH [226,227], and similar observations were obtained in experimental models of HCC development [285,286,287].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [226]
In the citing paper
“Co-housing wildtype mice with mice prone to MASH led to increased disease severity in wildtype mice, presumably due to a transfer of fecal microbiota (204).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [204]
In the citing paper
“In the MCD diet model, the microbiota has a key role in NASH exacerbation as demonstrated by experiments, in which co-housing transmitted NASH risk and antibiotics reduced NASH risk65.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [65]
In the citing paper
“Functional studies utilizing co-housing and faecal transplantation have provided evidence that dysbiosis is a transmissible driver of liver disease development and progression 65,89.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [65]
In the citing paper
“Similarly, dysbiosis represented a transmissible risk factor in a genetic NASH model in which NASH was triggered by inflammasome deficiency; co-housing of dysbiotic inflammasome-deficient mice with control mice resulted in the development of NASH in control mice65.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [65]
In the citing paper
“Association of bacterial composition with many diseases has been observed, including immune, inflammatory, and metabolic phenotypes.”
From The Gut Microbiome Contributes to a Substantial Proportion of the Variation in Blood Lipids (2015) · cites this paper as [5]
In the citing paper
“Disruption of the murine inflammasomes (see box 1) is associated with an increase in Bacteroidetes and reduction in Firmicutes and results in severe hepatic steatosis and inflammation.41”
From The gut microbiota and host health: a new clinical frontier (2016) · cites this paper as [41]
In the citing paper
“the NLRP6 and NLRP3 inflammasomes may exert protective effects against NAFLD/NASH through modulation of the gut microbiota.181”
From Interaction between microbiota and immunity in health and disease (2020) · cites this paper as [181]
In the citing paper
“Dysbiosis has been observed in mice deficient for inflammasomes components, including NLRP6, ASC, caspase-1, and IL-18 [131,132,133,134].”
From Gut Microbiota and Cancer: From Pathogenesis to Therapy (2019) · cites this paper as [134]
In the citing paper
“The Muc2-KO mouse possesses a distinct gut-associated bacterial community that is influenced by its altered genetic and immune states, as has been shown in other genetic knockout mouse models.4,53–55”
From Using Corticosteroids to Reshape the Gut Microbiome: Implications for Inflammatory Bowel Diseases (2015) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887
Self-citationDesign and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 1×
“Tlr9 –/– mice have been described in another repor”
BackgroundMartinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066
A role for mitochondria in nlrp3 inflammasome activation
Zhou, R., Yazdi, A. S., Menu, P., & Tschopp, J. (2011) · Nature · doi:10.1038/nature09663 · Cited by 5,602
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,728
Thioredoxin-interacting protein links oxidative stress to inflammasome activation
Zhou, R., Tardivel, A., Thorens, B., Choi, I., & Tschopp, J. (2010) · Nature Immunology · doi:10.1038/ni.1831 · Cited by 2,708
Cited by
Sorted by citations
Items 301–400 of 1,011
The intestinal microbiota: its role in health and disease
Biedermann, L., & Rogler, G. (2015) · European Journal of Pediatrics · doi:10.1007/s00431-014-2476-2 · Cited by 227
Gut-liver axis and probiotics: Their role in non-alcoholic fatty liver disease
Paolella, G. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i42.15518 · Cited by 222
Goldsmith, J. R., & Sartor, R. B. (2014) · Journal of Gastroenterology · doi:10.1007/s00535-014-0953-z · Cited by 224
Impaired Gut-Liver-Brain Axis in Patients with Cirrhosis
Ahluwalia, V., Betrapally, N. S., Hylemon, P. B., White, M. B., Gillevet, P. M., Unser, A. B., Fagan, A., Daita, K., Heuman, D. M., Zhou, H., et al. (2016) · Scientific Reports · doi:10.1038/srep26800 · Cited by 213
The NLR family of innate immune and cell death sensors
Sundaram, B., Tweedell, R. E., Kumar, S. P., & Kanneganti, T. (2024) · Immunity · doi:10.1016/j.immuni.2024.03.012 · Cited by 224
Molecular Pathogenesis of NASH
Caligiuri, A., Gentilini, A., & Marra, F. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091575 · Cited by 219
Intestinal Barrier and Permeability in Health, Obesity and NAFLD
Portincasa, P., Bonfrate, L., Khalil, M., Angelis, M. D., Calabrese, F. M., D’Amato, M., Wang, D. Q. ‐., & Ciaula, A. D. (2021) · Biomedicines · doi:10.3390/biomedicines10010083 · Cited by 219
Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease
Wieland, A. C., Frank, D. N., Harnke, B., & Bambha, K. M. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13376 · Cited by 211
Non-alcoholic fatty liver disease: What the clinician needs to know
Machado, M. V. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i36.12956 · Cited by 215
Li, X., Watanabe, K., & Kimura, I. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01882 · Cited by 216
Wang, W., Zhao, J., Gui, W., Sun, D., Dai, H., Xiao, L., Chu, H., Du, F., Zhu, Q., Schnabl, B., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14095 · Cited by 210
Neonatal selection by Toll-like receptor 5 influences long-term gut microbiota composition
Fulde, M., Sommer, F., Chassaing, B., van Vorst, K., Dupont, A., Hensel, M., Basic, M., Klopfleisch, R., Rosenstiel, P., Bleich, A., et al. (2018) · Nature · doi:10.1038/s41586-018-0395-5 · Cited by 206
Melatonin alleviates cadmium‐induced liver injury by inhibiting the TXNIP‐NLRP3 inflammasome
Cao, Z., Fang, Y., Lu, Y., Tan, D. X., Du, C., Li, Y., Ma, Q., Yu, J., Chen, M., Zhou, C., et al. (2017) · Journal of Pineal Research · doi:10.1111/jpi.12389 · Cited by 206
Caussy, C., Hsu, C., Lo, M., Liu, A., Bettencourt, R., Ajmera, V. H., Bassirian, S., Hooker, J., Sy, E., Richards, L., et al. (2018) · Hepatology · doi:10.1002/hep.29892 · Cited by 205
Using Corticosteroids to Reshape the Gut Microbiome: Implications for Inflammatory Bowel Diseases
Huang, E. Y., Inoue, T., Leone, V. A., Dalal, S., Touw, K., Wang, Y., Musch, M. W., Theriault, B., Higuchi, K., Donovan, S., et al. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000332 · Cited by 204
Obesity I: Overview and molecular and biochemical mechanisms
Lustig, R. H., Collier, D., Kassotis, C., Roepke, T. A., Kim, M. J., Blanc, E., Barouki, R., Bansal, A., Cave, M. C., Chatterjee, S., et al. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115012 · Cited by 203
Gut Microbiome and Obesity: A Plausible Explanation for Obesity
Sanmiguel, C. P., Gupta, A., & Mayer, E. A. (2015) · Current Obesity Reports · doi:10.1007/s13679-015-0152-0 · Cited by 210
Vujkovic-Cvijin, I., Sortino, O., Verheij, E., Sklar, J., Wit, F. W. N. M., Kootstra, N. A., Sellers, B. A., Brenchley, J. M., Ananworanich, J., van der Loeff, M. F. S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16222-8 · Cited by 207
Microbiota and Gut–Liver Axis: Their Influences on Obesity and Obesity‐Related Liver Disease
Vajro, P., Paolella, G., & Fasano, A. (2013) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e318284abb5 · Cited by 201
Propionate suppresses hepatic gluconeogenesis via GPR43/AMPK signaling pathway
Yoshida, H., Ishii, M., & Akagawa, M. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.07.022 · Cited by 206
Mechanisms of disease: inflammasome activation and the development of type 2 diabetes
Grant, R. W., & Dixit, V. D. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00050 · Cited by 204
Kim, H. S., Whon, T. W., Sung, H., Jeong, Y., Jung, E. S., Shin, N., Hyun, D., Kim, P. S., Lee, J., Lee, C. H., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20389-5 · Cited by 210
Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice
Mazagova, M., Wang, L., Anfora, A. T., Wissmueller, M., Lesley, S. A., Miyamoto, Y., Eckmann, L., Dhungana, S., Pathmasiri, W., Sumner, S., et al. (2015) · The FASEB Journal · doi:10.1096/fj.14-259515 · Cited by 199
Yu, J., Marsh, S., Hu, J., Feng, W., & Wu, C. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/2862173 · Cited by 199
The role of the gut microbiota in metabolic health
Janssen, A. W. F., & Kersten, S. (2015) · The FASEB Journal · doi:10.1096/fj.14-269514 · Cited by 209
Liang, D., Leung, R. K., Guan, W., & Au, W. W. (2018) · Gut Pathogens · doi:10.1186/s13099-018-0230-4 · Cited by 206
The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse
Morgan, A. P., Crowley, J. J., Nonneman, R. J., Quackenbush, C. R., Miller, C. N., Ryan, A. K., Bogue, M. A., Paredes, S. H., Yourstone, S., Carroll, I. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115225 · Cited by 197
Watanabe, S., Hashimoto, E., Ikejima, K., Uto, H., Ono, M., Sumida, Y., Seike, M., Takei, Y., Takehara, T., Tokushige, K., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12511 · Cited by 197
Therapeutic modulation of intestinal dysbiosis
Walker, A. W., & Lawley, T. D. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.09.008 · Cited by 209
Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy
Ma, J., Zhou, Q., & Li, H. (2017) · Nutrients · doi:10.3390/nu9101124 · Cited by 197
Innate sensors of pathogen and stress: Linking inflammation to obesity
Jin, C., & Flavell, R. A. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.06.022 · Cited by 197
Self-citationSharpton, S. R., Schnabl, B., Knight, R., & Loomba, R. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.11.010 · Cited by 194
Metabolic inflammation: Connecting obesity and insulin resistance
Dali‐Youcef, N., Mecili, M., Ricci, R., & Andrès, E. (2012) · Annals of Medicine · doi:10.3109/07853890.2012.705015 · Cited by 201
The immune tolerant phase of chronic HBV infection: new perspectives on an old concept
Bertoletti, A., & Kennedy, P. T. F. (2014) · Cellular and Molecular Immunology · doi:10.1038/cmi.2014.79 · Cited by 198
Protective Microbiota: From Localized to Long-Reaching Co-Immunity
Chiu, L., Bazin, T., Truchetet, M., Schaeverbeke, T., Delhaès, L., & Pradeu, T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01678 · Cited by 208
Obesity, fatty liver disease and intestinal microbiota
Arslan, N. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i44.16452 · Cited by 200
Of inflammasomes and pathogens – sensing of microbes by the inflammasome
Bauernfeind, F. G., & Hornung, V. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201771 · Cited by 198
Denou, E., Lolmède, K., Garidou, L., Pomié, C., Chabo, C., Lau, T. C., Fullerton, M. D., Nigro, G., Zakaroff‐Girard, A., Luche, É., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404169 · Cited by 197
Type I Interferon Responses Drive Intrahepatic T Cells to Promote Metabolic Syndrome
Ghazarian, M., Revelo, X. S., Nøhr, M. K., Luck, H., Zeng, K., Lei, H., Tsai, S., Schroer, S. A., Park, Y. J., Chng, M. H. Y., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aai7616 · Cited by 190
Kang, L., Li, P., Wang, D., Wang, T., Dong, H., & Qu, X. (2021) · Scientific Reports · doi:10.1038/s41598-021-84031-0 · Cited by 197
The Gut Microbiota and Liver Disease
Llorente, C., & Schnabl, B. (2015) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2015.04.003 · Cited by 195
Immune and inflammatory pathways in NASH
Ganz, M., & Szabó, G. (2013) · Hepatology International · doi:10.1007/s12072-013-9468-6 · Cited by 195
Giorgio, V., Miele, L., Principessa, L., Ferretti, F., Villa, M. P., Negro, V., Grieco, A., Alisi, A., & Nobili, V. (2014) · Digestive and Liver Disease · doi:10.1016/j.dld.2014.02.010 · Cited by 188
Innate Immune Receptors: Key Regulators of Metabolic Disease Progression
Jin, C., Henao‐Mejia, J., & Flavell, R. A. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.011 · Cited by 195
Self-citationDumas, M., Kinross, J. K., & Nicholson, J. K. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.11.001 · Cited by 187
On phagocytes and macular degeneration
Guillonneau, X., Eandi, C. M., Paques, M., Sahel, J.-A., Sapieha, P., & Sennlaub, F. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.06.002 · Cited by 185
Inflammasomes: far beyond inflammation
Henao‐Mejia, J., Elinav, E., Strowig, T., & Flavell, R. A. (2012) · Nature Immunology · doi:10.1038/ni.2257 · Cited by 188
Self-citationRapidly expanding knowledge on the role of the gut microbiome in health and disease
Cénit, M. C., Matzaraki, V., Tigchelaar, E. F., & Zhernakova, A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.05.023 · Cited by 197
Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds
Xu, C., Wan, X., Xu, L., Weng, H., Yan, M., Miao, M., Sun, Y., Xu, G.-Y., Dooley, S., Li, Y., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.01.019 · Cited by 186
Zhou, S.-S., Xu, J., Zhu, H., Wu, J., Xu, J., Yan, R., Li, X., Liu, H.-H., Duan, S.-M., Wang, Z., et al. (2016) · Scientific Reports · doi:10.1038/srep22474 · Cited by 186
The germ-organ theory of non-communicable diseases
Byndloss, M. X., & Bäumler, A. J. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.158 · Cited by 195
The role of diet and intestinal microbiota in the development of metabolic syndrome
Santos-Marcos, J. A., Pérez‐Jiménez, F., & Camargo, A. (2019) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2019.03.017 · Cited by 188
Targeting fatty acid metabolism to improve glucose metabolism
Stinkens, R., Goossens, G. H., Jocken, J. W. E., & Blaak, E. E. (2015) · Obesity Reviews · doi:10.1111/obr.12298 · Cited by 183
Bae, H. R., Kim, D. H., Park, M. H., Lee, B., Kim, M. J., Lee, E. K., Chung, K. W., Kim, S. M., Im, D., & Chung, H. Y. (2016) · Oncotarget · doi:10.18632/oncotarget.12119 · Cited by 186
Kushiyama, A., Nakatsu, Y., Matsunaga, Y., Yamamotoya, T., Mori, K., Ueda, K., Inoue, Y., Sakoda, H., Fujishiro, M., Ono, H., et al. (2016) · Mediators of Inflammation · doi:10.1155/2016/8603164 · Cited by 188
Therapeutic Landscape for NAFLD in 2020
Neuschwander‐Tetri, B. A. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.051 · Cited by 184
Integration of Innate Immune Signaling
Thaiss, C. A., Levy, M., Itav, S., & Elinav, E. (2016) · Trends in Immunology · doi:10.1016/j.it.2015.12.003 · Cited by 189
Self-citationProietti, M., Cornacchione, V., Rezzonico Jost, T., Romagnani, A., Faliti, C. E., Perruzza, L., Rigoni, R., Radaelli, E., Caprioli, F., Preziuso, S., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.010 · Cited by 181
Gut Dysbiosis and Muscle Aging: Searching for Novel Targets against Sarcopenia
Picca, A., Fanelli, F., Calvani, R., Mulè, G., Pesce, V., Sisto, A., Pantanelli, C., Bernabei, R., Landi, F., & Marzetti, E. (2018) · Mediators of Inflammation · doi:10.1155/2018/7026198 · Cited by 181
Nlrp6- and ASC-Dependent Inflammasomes Do Not Shape the Commensal Gut Microbiota Composition
Mamantopoulos, M., Ronchi, F., Van Hauwermeiren, F., Vieira-Silva, S., Yilmaz, B., Martens, L., Saeys, Y., Drexler, S. K., Yazdi, A. S., Raes, J., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.07.011 · Cited by 181
Martínez, I., Muller, C. E., & Walter, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069621 · Cited by 181
Milk sphingomyelin improves lipid metabolism and alters gut microbiota in high fat diet-fed mice
Norris, G. H., Jiang, C., Ryan, J. A., Porter, C. M., & Blesso, C. N. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.12.003 · Cited by 184
Estrogen and Microbiota Crosstalk: Should We Pay Attention?
Chen, K. L., & Madak‐Erdogan, Z. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.08.001 · Cited by 181
Intestinal microbiota and type 2 diabetes: From mechanism insights to therapeutic perspective
Han, J.-L., & Lin, H. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i47.17737 · Cited by 188
Mu, H., Zhou, Q., Yang, R., Zeng, J., Li, X., Zhang, R., Tang, W., Li, H., Wang, S., Shen, T., et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.585066 · Cited by 181
Farrell, G. C., Haczeyni, F., & Chitturi, S. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-10-8684-7_3 · Cited by 178
The innate immune response during liver inflammation and metabolic disease
Bieghs, V., & Trautwein, C. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.04.005 · Cited by 176
Gut microbiota and liver diseases
Minemura, M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i6.1691 · Cited by 178
How is inflammation initiated? Individual influences of IL-1, IL-18 and HMGB1
Keyel, P. A. (2014) · Cytokine · doi:10.1016/j.cyto.2014.03.007 · Cited by 182
Inflammasomes and Metabolic Disease
Henao‐Mejia, J., Elinav, E., Thaiss, C. A., & Flavell, R. A. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021113-170324 · Cited by 176
Self-citationInterleukin-1 Family Cytokines: Keystones in Liver Inflammatory Diseases
Barbier, L. A., Ferhat, M., Salamé, E., Robin, A., Herbelin, A., Gombert, J., Silvain, C., & Barbarin, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02014 · Cited by 178
Parental Dietary Fat Intake Alters Offspring Microbiome and Immunity
Myles, I. A., Fontecilla, N. M., Janelsins, B., Vithayathil, P. J., Segre, J. A., & Datta, S. K. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301057 · Cited by 177
Lighting the fires within: the cell biology of autoinflammatory diseases
Park, H., Bourla, A. B., Kastner, D. L., Colbert, R. A., & Siegel, R. M. (2012) · Nature reviews. Immunology · doi:10.1038/nri3261 · Cited by 178
Gut Microbiota, Low-grade Inflammation, and Metabolic Syndrome
Chassaing, B., & Gewirtz, A. T. (2013) · Toxicologic Pathology · doi:10.1177/0192623313508481 · Cited by 183
Pathogenic role of the gut microbiota in gastrointestinal diseases
Nagao‐Kitamoto, H., Kitamoto, S., Kuffa, P., & Kamada, N. (2016) · Intestinal Research · doi:10.5217/ir.2016.14.2.127 · Cited by 178
Inflammasomes and host defenses against bacterial infections
Vladimer, G. I., Marty-Roix, R., Ghosh, S., Weng, D., & Lien, E. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2012.11.008 · Cited by 173
Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH
Wan, X., Xu, C., Yu, C., & Li, Y. (2016) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2016/6489012 · Cited by 176
IL-1 family cytokines trigger sterile inflammatory disease
Lukens, J. R., Gross, J. M., & Kanneganti, T. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00315 · Cited by 178
Ma, J., Hong, Y., Zheng, N., Xie, G., Lyu, Y., Gu, Y., Xi, C., Chen, L., Wu, G., Li, Y., et al. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1763770 · Cited by 171
Non-alcoholic steatohepatitis: a microbiota-driven disease
Moschen, A. R., Kaser, S., & Tilg, H. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.05.009 · Cited by 176
IL-18 Production from the NLRP1 Inflammasome Prevents Obesity and Metabolic Syndrome
Murphy, A. J., Kraakman, M. J., Kammoun, H. L., Dragoljevic, D., Lee, M. K. S., Lawlor, K. E., Wentworth, J. M., Vasanthakumar, A., Gerlic, M., Whitehead, L. W., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.09.024 · Cited by 171
The intersection of cell death and inflammasome activation
Vince, J. E., & Silke, J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2205-2 · Cited by 180
Expanding role of gut microbiota in lipid metabolism
Ghazalpour, A., Cespedes, I., Bennett, B. J., & Allayee, H. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000278 · Cited by 177
The role of the gut microbiome in chronic liver disease: the clinical evidence revised
Schwenger, K. J. P., Clermont‐Dejean, N. M., & Allard, J. P. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.04.004 · Cited by 179
Sharpton, S. R., Ajmera, V. H., & Loomba, R. S. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.08.065 · Cited by 177
Intestinal Microbiota and Nonalcoholic Steatohepatitis
Brandl, K., & Schnabl, B. (2017) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000349 · Cited by 169
González, N., Prieto, I., del Puerto‐Nevado, L., Portal‐Núñez, S., Ardura, J. A., Cortón, M., Fernández‐Fernández, B., Aguilera, Ó., Gómez‐Guerrero, C., Mas, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14472 · Cited by 177
Harsch, I. A., & Konturek, P. C. (2018) · Medical Sciences · doi:10.3390/medsci6020032 · Cited by 173
Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet
Mokhtari, Z., Gibson, D. L., & Hekmatdoost, A. (2017) · Advances in Nutrition · doi:10.3945/an.116.013151 · Cited by 170
The interplay between the innate immune system and the microbiota
Thaiss, C. A., Levy, M., Suez, J., & Elinav, E. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.10.016 · Cited by 176
Self-citationRole of the intestinal microbiome in liver disease
Henao‐Mejia, J., Elinav, E., Thaiss, C. A., Licona-Limón, P., & Flavell, R. A. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.07.001 · Cited by 169
Self-citationRole of free fatty acid receptors in the regulation of energy metabolism
Hara, T., Kashihara, D., Ichimura, A., Kimura, I., Tsujimoto, G., & Hirasawa, A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.06.002 · Cited by 174
Jørgensen, S. F., Trøseid, M., Kummen, M., Anmarkrud, J. A., Michelsen, A. E., Osnes, L., Holm, K., Høivik, M. L., Rashidi, A., Dahl, C. P., et al. (2016) · Mucosal Immunology · doi:10.1038/mi.2016.18 · Cited by 170
Antibiotic effects on gut microbiota and metabolism are host dependent
Fujisaka, S., Ussar, S., Clish, C. B., Devkota, S., Dreyfuss, J. M., Sakaguchi, M., Soto, M., Konishi, M., Softic, S., Altındiş, E., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86674 · Cited by 171
Oh, N. S., Lee, J. Y., Kim, Y.-T., Kim, S. H., & Lee, J.-H. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1785803 · Cited by 166
Toubal, A., Kiaf, B., Beaudoin, L., Cagninacci, L., Rhimi, M., Fruchet, B., da Silva, J., Corbett, A. J., Simoni, Y., Lantz, O., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17307-0 · Cited by 165
Goldszmid, R. S., & Trinchieri, G. (2012) · Nature Immunology · doi:10.1038/ni.2422 · Cited by 175
Ciaula, A. D., Baj, J., Garruti, G., Celano, G., Angelis, M. D., Wang, H. H., Palo, D. M. D., Bonfrate, L., Wang, D. Q. ‐., & Portincasa, P. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082648 · Cited by 166
Pathophysiology of NASH: perspectives for a targeted treatment
Marra, F., & Lotersztajn, S. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990344 · Cited by 163
Influence of Gut Microbiota on Subclinical Inflammation and Insulin Resistance
Carvalho, B. M., & Saad, M. J. A. (2013) · Mediators of Inflammation · doi:10.1155/2013/986734 · Cited by 166
Metadata
- Authors
- Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., Camporez, J.-P., Shulman, G. I., Gordon, J. I., Hoffman, H. M., & Flavell, R. A.
- Affiliations
- Yale University (US)
- Washington University in St. Louis (US)
- Howard Hughes Medical Institute (US)
- University of California San Diego (US)
- Corresponding author
- Flavell, Richard A.
- ORCID
- Venue
- Nature
- Published
- 2012-02
- Volume
- 482
- Issue
- 7384
- Pages
- 179-185
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3276682
- OpenAlex
- W2144275312
- Cited by
- 2,435
- References
- 41
- Citations by year
- 2026: 83 · 2025: 103 · 2024: 137 · 2023: 165 · 2022: 158 · 2021: 182 · 2020: 215 · 2019: 188 · 2018: 197 · 2017: 184 · 2016: 172 · 2015: 195 · 2014: 181 · 2013: 185 · 2012: 85
- FWCI
- 154.13
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Crohn's and Colitis Foundation
- U.S. Public Health Service (K08A1085038)
- National Heart, Lung, and Blood Institute (T32HL007974)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK45735, R01-DK40936, R01DK040936, U24DK059635, R01DK076674, R24DK085638, P30DK045735)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, NLRP3 inflammasome, NLRP6 inflammasome, IL-18, gut dysbiosis, metabolic syndrome, obesity, hepatic steatosis, liver inflammation, TLR4, TLR9, TNF-α, Porphyromonadaceae, host-microbiota interactions, autoinflammatory disease
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Carrier Proteins, Choline, Colon, Cytoskeletal Proteins, Disease Models, Animal, Fatty Liver, Inflammation, Male, Methionine, Mice, Inbred C57BL, Obesity, Receptors, Cell Surface, RNA, Ribosomal, 16S, Tumor Necrosis Factor-alpha, Disease Progression, Interleukin-18, Apoptosis Regulatory Proteins, Toll-Like Receptor 4, Toll-Like Receptor 9, Mice, CARD Signaling Adaptor Proteins, Metagenome, Inflammasomes, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
